RecruitingNCT05786664
Breast Cancer Survivorship Biorepository
A Comprehensive Breast Cancer Survivorship Biorepository
Sponsor
University of Southern California
Enrollment
1,300 participants
Start Date
Apr 11, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria4
- Women of all racial and ethnic groups 18 years of age or older
- Women with a diagnosis of invasive breast cancer (stages I-III) within the past 7 years
- Women who have completed active treatment for breast cancer (surgery, chemotherapy, HER2-directed therapy and radiation)
- Prior participation on clinical trials is allowed
Exclusion Criteria5
- Current receipt of interventional clinical trial participation
- Stage IV (metastatic) cancer
- Prior history of recurrence (except recurrence following ductal carcinoma in situ)
- Inability to give informed consent
- Unable to speak English, Spanish, Chinese, or Korean
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of blood samples
OTHERElectronic Health Record Review
Review of records
OTHERQuality-of-Life Assessment
Complete quality-of-life questionnaires
OTHERSurvey Administration
Complete surveys
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05786664
Related Trials
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT0360696730 locations
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT0567320010 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377475 locations
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT045504944 locations
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT054227946 locations